Renaissance Technologies LLC acquired a new position in Medtronic PLC (NYSE:MDT) during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 434,000 shares of the medical technology company’s stock, valued at approximately $38,518,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Hudock Capital Group LLC grew its stake in shares of Medtronic PLC by 0.5% in the second quarter. Hudock Capital Group LLC now owns 2,195 shares of the medical technology company’s stock valued at $194,000 after buying an additional 11 shares in the last quarter. Bollard Group LLC grew its stake in shares of Medtronic PLC by 0.4% in the second quarter. Bollard Group LLC now owns 3,651 shares of the medical technology company’s stock valued at $324,000 after buying an additional 14 shares in the last quarter. Triangle Securities Wealth Management grew its stake in shares of Medtronic PLC by 0.3% in the second quarter. Triangle Securities Wealth Management now owns 4,396 shares of the medical technology company’s stock valued at $390,000 after buying an additional 15 shares in the last quarter. IFC Holdings Incorporated FL grew its stake in shares of Medtronic PLC by 0.3% in the second quarter. IFC Holdings Incorporated FL now owns 5,673 shares of the medical technology company’s stock valued at $501,000 after buying an additional 17 shares in the last quarter. Finally, North Star Investment Management Corp. grew its stake in shares of Medtronic PLC by 1.1% in the second quarter. North Star Investment Management Corp. now owns 1,995 shares of the medical technology company’s stock valued at $177,000 after buying an additional 22 shares in the last quarter. Institutional investors own 81.37% of the company’s stock.

A number of research firms have recently issued reports on MDT. Needham & Company LLC reiterated a “buy” rating and issued a $94.00 target price on shares of Medtronic PLC in a research note on Thursday, November 9th. SunTrust Banks, Inc. restated a “buy” rating and set a $96.00 price objective on shares of Medtronic PLC in a research note on Friday, November 3rd. Cowen and Company restated a “buy” rating and set a $95.00 price objective on shares of Medtronic PLC in a research note on Friday, November 3rd. BMO Capital Markets restated an “outperform” rating and set a $89.00 price objective (down previously from $92.00) on shares of Medtronic PLC in a research note on Tuesday, October 10th. Finally, Leerink Swann restated a “market perform” rating and set a $85.00 price objective (down previously from $88.00) on shares of Medtronic PLC in a research note on Monday, October 9th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $87.88.

TRADEMARK VIOLATION WARNING: This story was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/14/renaissance-technologies-llc-acquires-new-holdings-in-medtronic-plc-mdt.html.

Shares of Medtronic PLC (NYSE MDT) opened at $79.20 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.40 and a current ratio of 1.64. The firm has a market capitalization of $107,459.70, a price-to-earnings ratio of 16.92, a price-to-earnings-growth ratio of 2.19 and a beta of 1.00. Medtronic PLC has a 12 month low of $69.35 and a 12 month high of $89.72.

Medtronic PLC (NYSE:MDT) last announced its earnings results on Tuesday, August 22nd. The medical technology company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.04. The firm had revenue of $7.39 billion for the quarter, compared to the consensus estimate of $7.44 billion. Medtronic PLC had a return on equity of 12.92% and a net margin of 13.75%. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.03 EPS. equities research analysts expect that Medtronic PLC will post 4.66 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, October 20th. Shareholders of record on Friday, September 29th were paid a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a yield of 2.32%. The ex-dividend date was Thursday, September 28th. Medtronic PLC’s payout ratio is currently 61.95%.

In other news, EVP Bryan C. Hanson sold 16,000 shares of Medtronic PLC stock in a transaction on Monday, October 16th. The stock was sold at an average price of $78.03, for a total transaction of $1,248,480.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Omar Ishrak sold 140,407 shares of Medtronic PLC stock in a transaction on Friday, September 15th. The shares were sold at an average price of $81.63, for a total value of $11,461,423.41. Following the transaction, the chief executive officer now owns 668,503 shares in the company, valued at $54,569,899.89. The disclosure for this sale can be found here. 0.31% of the stock is owned by insiders.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.